ACLX

Arcellx, Inc.

Company with tickers: ACLX

CIK

1786205

CUSIP

03940C100

Shares Outstanding

58,506,348

Website

https://www.arcellx.com

Investor Relations

https://investors.gilead.com/overview/default.aspx

13F Activity (30d)

120 filings 119 filers

Press releases and events scraped from the company's investor relations website. News and event listings link back to the original source.

Date	Headline
2026-06-12	Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
2026-06-11	National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
2026-06-08	Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
2026-06-08	Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
2026-06-05	Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
2026-06-04	Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
2026-06-02	Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
2026-05-27	Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)
2026-05-22	FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
2026-05-22	Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors